Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

6082 ARTÍCULOS , VIENDO DEL 5941 AL 5955

Managing Dystonia in Partington Syndrome

Pichon E, Alioth A, Catalano Chiuvé S, Zacharia A, Ruiz-Lopez M, Breen DP, Zangas-Gehri F, Draye F, Curie A, Wilson D, Fung VSC, Duma S, Fluss J, Bally JF.

Mov Disord Clin Pract. 2026 Feb;13(2):533-540. doi: 10.1002/mdc3.70356. Epub 2025 Sep 30.

Modeling cerebral palsy in animals

Quinlan KA, Reedich EJ, Mena Avila E, Moline BC, Genry LT, Detloff MR, Katholi BR, Gaebler-Spira D, Aravamuthan BR.

Dev Med Child Neurol. 2026 Feb;68(2):158-174. doi: 10.1111/dmcn.70007. Epub 2025 Oct 3.

GPi-DBS for SERAC1-Related Dystonia-Parkinsonism

Yahya V, Di Maio A, Treddenti M, Tundo L, Scacciatella G, Masetti C, Pengo M, Casellato C, Lattanzi D, Egidi M, Marceglia S, Bocci T, Priori A, Oggioni G.

Mov Disord Clin Pract. 2026 Feb;13(2):568-571. doi: 10.1002/mdc3.70332. Epub 2025 Aug 30.

TDP-43 proteinopathies and neurodegeneration: insights from Caenorhabditis elegans models

Pir GJ, Buddenkotte J, Alam MA, Own A, Eck RJ, Kraemer BC, Mandelkow E, Steinhoff M.

FEBS J. 2026 Jan;293(2):348-384. doi: 10.1111/febs.70239. Epub 2025 Sep 2.

The gut-brain axis: role of gut microbiota in neurological disease pathogenesis and pharmacotherapeutics

Aijaz M, Ahmad M, Ahmad S, Afzal M, Kothiyal P.

Naunyn Schmiedebergs Arch Pharmacol. 2026 Feb;399(4):4879-4905. doi: 10.1007/s00210-025-04776-7. Epub 2025 Nov 4.

Mapping social participation interventions for adults with a neurodegenerative condition: a scoping review of in-person and digital community approaches

Trotman H, Sakellariou D, Wood F, Hamana K.

Disabil Rehabil. 2026 Jan;48(1):1-16. doi: 10.1080/09638288.2025.2499582. Epub 2025 May 6.

CRISPR-Cas technologies in neurodegenerative disorders: mechanistic insights, therapeutic potential, and translational challenges

Yashooa RK, Nabi AQ, Smail SW, Azeez SS, Nooh WA, Mustafa SA, Al-Farha AA, Capitanio N, Shekha MS.

Front Neurol. 2026 Jan 27;16:1737468. doi: 10.3389/fneur.2025.1737468. eCollection 2025.

Role of FK506 binding protein 51 in central nervous system diseases

Peng H, Wei Y, Qiu Y, Bi R, Zeng L, Hu B, Li Y.

Front Mol Neurosci. 2026 Jan 12;18:1725945. doi: 10.3389/fnmol.2025.1725945. eCollection 2025.

The quest to restore neuronal structure: Targeting cytoskeletal proteins in neurodegenerative diseases

Selvaraj C, Desai D, Sumitha E.

Adv Protein Chem Struct Biol. 2026;150:397-422. doi: 10.1016/bs.apcsb.2025.10.026. Epub 2025 Nov 18.

The clinical phenotype of carriers of intermediate alleles in the huntingtin gene: A scoping review

van Hofslot A, Oosterloo M, de Jong JJA, Andriessen RL, de Bot ST, Linden DEJ.

J Huntingtons Dis. 2026 Feb;15(1):3-19. doi: 10.1177/18796397251397683. Epub 2025 Dec 17.

Innovative Interventions: Postbiotics and Psychobiotics in Neurodegenerative Disease Treatment

Gupta MK, Chauhan K, Bhardwaj S, Srivastava R.

Probiotics Antimicrob Proteins. 2026 Mar;18(2):2818-2837. doi: 10.1007/s12602-025-10632-0. Epub 2025 Jun 27.

Machine learning and deep learning in clinical practice: Advancing neurodegenerative disease diagnosis with multimodal markers

Zarei O, Talebi Moghaddam M, Moradi Vastegani S.

Brain Res Bull. 2026 Jan;234:111667. doi: 10.1016/j.brainresbull.2025.111667. Epub 2025 Dec 1.

The future of BRD9 inhibitors: a patent perspective (2019-present)

Boccia E, Terracciano S, Chini MG, Bifulco G, Lauro G.

Expert Opin Ther Pat. 2026 Feb;36(2):145-157. doi: 10.1080/13543776.2025.2606811. Epub 2025 Dec 24.

Network pharmacology approach to unravel the neuroprotective potential of natural products: a narrative review

Singh P, Borkar M, Doshi G.

Mol Divers. 2026 Feb;30(1):59-100. doi: 10.1007/s11030-025-11198-3. Epub 2025 Apr 25.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias